A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
← catalyst calendarNCT07659795 · readout ≤ 315 d
Sponsored by Verastem, Inc. (industry) · VSTM — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
150estimated
Sites
10
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-28 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colorectal Cancer
Interventions
- Drug: VS-7375
- Drug: cetuximab
- Drug: panitumumab
- Drug: Cetuximab + mFOLFOX6
Primary outcomes
what the primary-completion date above is the date OFConfirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only
measured 6 months
To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC
measured 6 months
To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC
measured 6 months
Permalink · VSTM's whole pipeline · Catalyst calendar · Every registered study · What changed